1 / 5

How to Find the Right Patients for “Cancer Immunotherapy”?

Cancer issue is always the focus of health topics, as http://www.creative-peptides.com/services/custom-gmp-peptide-synthesis-services.html shows.

ChloeMica
Télécharger la présentation

How to Find the Right Patients for “Cancer Immunotherapy”?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. How to Find the Right Patients for “Cancer Immunotherapy”? Editor: Elaine Company: Creative Peptides Website: http://www.creative-peptides.com/ Tel: 1-516-669-8109 Email: contact@creative-peptides.com

  2. Dr. James P. Allison from the MD Anderson Cancer Center has made great efforts in the field of cancer immunotherapy research, which has helped doctors to save countless lives of cancer patients. According to his findings, immunotherapy is designed to allow patients with malignant melanoma prolong survival from less than 1 year to 10 years. In recent days, a new published report with his participation is expected to help achieve a more accurate cancer immunotherapy, as well as Custom GMP Peptide research. As is known, great progress has been made in the field of immunology in the past decade, but optimism about the clinical application of currently available vaccine approaches is based more on surrogate endpoints than on clinical regression. On August 1st, a study published in the journal Cancer Discovery has displayed modern advance in cancer research. Scientists found that early tumor biopsy during treatment of immune response analysis will help predict which patients can benefit from the melanoma-specific immune checkpoints blocking drugs.

  3. Success of immune checkpoint inhibitors has made great progress in such treatment of metastatic melanoma. Over the past few years, FDA has approved a number of treatment options, while a large number of clinical trials are still underway. However, what can not be ignored is that most patients do not respond to these therapies, some patients have experienced serious toxicity. Given the complexity of the patients’ response to the inspection point depressants, it’s necessary to find ways to accurately predict which patients can benefit from this type of therapy biomarker, such as Glucagon-Like-Peptide. Although there are many previous reports about pre-treatment for tumor biopsy-related genomes and immune markers, the immune checkpoint blocking therapy is still complicated. These biomarkers are not very effective in responders and non-responders. Thus, scientists need to find a better biomarker, in order to optimize the use of such therapies. In this study, most scientists believe that the assessment of adaptive immune response should be in the early treatment after the starting process, which may be more valuable than the analyzed pre-treatment samples. This study about mechanisms of lung cancer immune escape provides theoretical foundation for new strategy of lung cancer immunotherapy.

  4. Developing more effective anticancer vaccine has been one of the major goals of cancer immunotherapy. The cloning and characterization of tumor associated antigens, and the i-dentification of the epitopes that can be recognized by cytotoxic T lymphocytes (CTLs) has opened new possibilities for cancer immunotherapy. Evaluating the immunotherapeutic application of tumor-associated melanoma antigen gene ( MAGE)-1, and-3 as the targets for lung cancer immunotherapy could also be significant as well, especially for Fertagyl in disease treatment. In addition, researches also found that before accepting CTLA-4 inhibitor ipilimumab treatment, there is no immune biomarkers difference between responders and non-responders, but after the start of treatment, the responder tumors density of killer T cells is significantly higher. The findings could to find more accurate checkpoint blocking for mass patients in the immune therapy, enabling to avoid potential side effects and unnecessary expense. Source(Read full text): https://www.behance.net/gallery/42443501/How-to-Find-the-Right-Patients-for-Cancer-Immunotherapy

  5. Creative Peptides focuses on the process development of bioactive peptides. It provides researchers with manufacturing services to the peptide manufacturers for the biopharmaceutical market. The goal is to offer a high-quality service for all the peptide development and manufacturing needs. Visit http://www.creative-peptides.com/ to know more about Creative Peptides. About Author

More Related